Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony V Moorman

Showing results (31-40 of 155) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trialsAnthony V Moorman, Hazel Robinson, Claire Schwab, et al.
Haematologica|July 10, 2009
Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11-13;q11) show recurrent involvement of genes at 20q11.21Qian An, Sarah L Wright, Anthony V Moorman, et al.
Haematologica|March 19, 2026
B-cell precursor acute lymphoblastic leukaemia with <i>IGH::CEBP</i> rearrangement: what have we learnt over the years?Ahlam Alqahtani, Kent T M Fung, Letizia Marchetti, et al.
Cancer Cell International|November 7, 2025
Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemiaHayden L Bell, Helen J Blair, Mankaran Singh, et al.
British Journal of Haematology|April 7, 2009
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trialsKeith Wheatley, Cassandra L Brookes, Andrew J Howman, et al.
Cancer Cell International|September 15, 2023
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemiaHayden L Bell, Helen J Blair, Mankaran Singh, et al.
Haematologica|March 20, 2013
Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical featuresClaire J Schwab, Lucy Chilton, Heather Morrison, et al.
Blood|April 14, 2010
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsDavid Grimwade, Robert K Hills, Anthony V Moorman, et al.
Genes, Chromosomes & Cancer|February 22, 2007
Molecular cytogenetic characterization of TCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemiaKerry E Barber, Christine J Harrison, Zoe J Broadfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trialsClaire H Seedhouse, Martin Grundy, Paul White, et al.
Pageof 16

Showing results (31-40 of 155) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trialsAnthony V Moorman, Hazel Robinson, Claire Schwab, et al.
Haematologica|July 10, 2009
Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11-13;q11) show recurrent involvement of genes at 20q11.21Qian An, Sarah L Wright, Anthony V Moorman, et al.
Haematologica|March 19, 2026
B-cell precursor acute lymphoblastic leukaemia with <i>IGH::CEBP</i> rearrangement: what have we learnt over the years?Ahlam Alqahtani, Kent T M Fung, Letizia Marchetti, et al.
Cancer Cell International|November 7, 2025
Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemiaHayden L Bell, Helen J Blair, Mankaran Singh, et al.
British Journal of Haematology|April 7, 2009
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trialsKeith Wheatley, Cassandra L Brookes, Andrew J Howman, et al.
Cancer Cell International|September 15, 2023
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemiaHayden L Bell, Helen J Blair, Mankaran Singh, et al.
Haematologica|March 20, 2013
Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical featuresClaire J Schwab, Lucy Chilton, Heather Morrison, et al.
Blood|April 14, 2010
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsDavid Grimwade, Robert K Hills, Anthony V Moorman, et al.
Genes, Chromosomes & Cancer|February 22, 2007
Molecular cytogenetic characterization of TCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemiaKerry E Barber, Christine J Harrison, Zoe J Broadfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trialsClaire H Seedhouse, Martin Grundy, Paul White, et al.
Pageof 16